Alendronate treatment in cats with persistent ionized hypercalcemia: A retrospective cohort study of 20 cases

Alendronate treatment in cats with persistent ionized hypercalcemia: A retrospective cohort study of 20 cases

Abstract Background Limited information is available concerning treatment of ionized hypercalcemia in cats. Hypothesis/Objectives Describe clinical findings in a cohort of cats with persistent ionized hypercalcemia and evaluate long‐term tolerance and efficacy of alendronate in these patients. Anima...

Full description

Bibliographic Details
Main Authors:	Maxime Kurtz, Loïc Desquilbet, Justine Maire, Fiona Da Riz, Morgane Canonne‐Guibert, Ghita Benchekroun, Christelle Maurey
Format:	Article
Language:	English
Published:	Wiley 2022-11-01
Series:	Journal of Veterinary Internal Medicine
Subjects:	bisphosphonates calcium chronic kidney disease urolithiasis
Online Access:	https://doi.org/10.1111/jvim.16508

Similar Items

The Efficacy of Alendronate Treatment in Ambulatory Stroke Patients
by: Nihal ÖZARAS, et al.
Published: (2016-04-01)

Alendronate reduces periosteal microperfusion in vivo
by: Danielle N. Kundert, et al.
Published: (2023-09-01)

Successful management with bisphosphonate treatment in a child with tuberculosis-associated hypercalcemia
by: Suna Kılınç, et al.
Published: (2020-08-01)

Long-term treatment with alendronate increases the surgical difficulty during simple exodontias – an in vivo observation in Holtzman rats
by: Conte-Neto Nicolau, et al.
Published: (2012-07-01)

Efficacy and Safety of Generic Alendronate for Osteoporosis Treatment
by: Jarusriwanna A, et al.
Published: (2024-02-01)

Feedback-Controlled Release of Alendronate from Composite Microparticles
by: Sofia S. H. Matrali, et al.
Published: (2020-07-01)

An interesting case of bisphosphonate resistant hypercalcemia in acute myelogenous leukemia (AML)
by: Sara M. Cohen, et al.
Published: (2022-12-01)

Disease-Modifying Potential of Metformin and Alendronate in an Experimental Mouse Model of Osteoarthritis
by: Lyudmila Belenska-Todorova, et al.
Published: (2021-08-01)

Immobilization of Alendronate on Zirconium Phosphate Nanoplatelets
by: Anna Donnadio, et al.
Published: (2023-02-01)

Atypical femoral fracture in the setting of alendronate treatment for osteoporosis: a case report and literature review
by: Eric D. Van Baarsel, et al.
Published: (2019-07-01)

Effect of Zoledronic Acid and Alendronate on Bone Edema and Pain in Spontaneous Osteonecrosis of the Knee: A New Paradigm in the Medical Management
by: Sanjay Agarwala, et al.

Histologic evaluation of femoral nerve demyelinating and axonal neuropathy in Wistar rats due to alendronate intake: a randomised study
by: Papamitsou Theodora, et al.
Published: (2020-02-01)

Validation and Feasibility of the Medication Acceptability Questionnaire to Investigate Tablet and Liquid Alendronic Acid with Older Hospital Patients
by: Sion Scott, et al.
Published: (2018-08-01)

Cinacalcet increases renal calcium excretion in PTHrP-mediated hypercalcemia: a case report
by: Samya Faiq, et al.
Published: (2023-06-01)

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
by: Antonino Catalano, et al.
Published: (2021-05-01)

Refractory hypercalcemia of malignancy: a problem with many potential roots
by: Azeez Farooki, et al.
Published: (2023-05-01)

Acetabular and sacral insufficiency fractures in a patient with a long-term history of Alendronate consumption; a case report
by: Kaveh Gharanizadeh, et al.
Published: (2023-03-01)

The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial
by: Pokpong Piriyakhuntorn, et al.
Published: (2023-05-01)

The effect on the gastrointestinal tract of various forms of alendronate in comorbid patients taking NSAIDs
by: I. A. Shafieva, et al.
Published: (2021-04-01)

Cardioprotective effects of alendronate bisphosphonate in patients with ischemic heart disease associated with type 2 diabetes mellitus and osteoporosis
by: S. N. Shilov, et al.
Published: (2021-05-01)

The Findings of Bone Mineral Densitometry Following Preventive Treatment with Alendronate in Menopausal Women with Osteopenia; What is the Best Dose?
by: Mansour Karimifar, et al.
Published: (2020-12-01)

Efficacy of Alendronate and Cholecalciferol Combination in the Treatment of Osteoporosis in Patients with Chronic Viral Hepatitis Receiving Antiviral Therapy: Report of Two Cases
by: İlke Coşkun Benlidayı, et al.
Published: (2015-08-01)

An Evaluation of Nutritional Factors on The Prevalence of Urolithiasis in Cats at The Veterinary Teaching Hospital, Universitas Airlangga During 2017-2019
by: Daffa Amanul Mahdi, et al.
Published: (2023-10-01)

Studies on Feline lower Urinary Tract Disease in Egypt Cat Population
by: Shimaa Ayoub, et al.
Published: (2024-01-01)

Increasing Dietary Potassium Chloride Promotes Urine Dilution and Decreases Calcium Oxalate Relative Supersaturation in Healthy Dogs and Cats
by: Esther Bijsmans, et al.
Published: (2021-06-01)

Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-Study
by: Nurten Eskiyurt, et al.
Published: (2012-04-01)

First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
by: Vishal R Tandon, et al.
Published: (2014-01-01)

Ionized hypercalcemia in 238 cats from a referral hospital population (2009‐2019)
by: Sophie E. Broughton, et al.
Published: (2023-01-01)

The effect of attenuating dietary phosphate restriction on blood ionized calcium concentrations in cats with chronic kidney disease and ionized hypercalcemia
by: Rebecca F. Geddes, et al.
Published: (2021-03-01)

Cystinuria in Dogs and Cats: What Do We Know after Almost 200 Years?
by: Simona Kovaříková, et al.
Published: (2021-08-01)

Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial
by: Darrell H. S. Tan, et al.
Published: (2019-11-01)

Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis
by: Swati Rajput, et al.
Published: (2023-02-01)

Osteonecrosis of the jaw associated to biphosponates in Cali-Colombia
by: Miguel Evelio León Arcila, et al.
Published: (2020-04-01)

URETEROCELE, IN COMBINATION WITH UROLITHIASIS: CLINIC, DIAGNOSTICS AND TREATMENT
by: V N Shirshov, et al.
Published: (2016-03-01)

Prevalence of urolithiasis in Sarawak and associated risk factors: An ultrasonagraphy‐based cross‐sectional study
by: Kamal Raj Perumal, et al.
Published: (2023-01-01)

Comparison of laparoscopic ureterolithotomy and retrograde lithotripsy in the treatment of proximal ureteral stones
by: V. A. Vorobev, et al.
Published: (2022-09-01)

Bisphosphonate induced hypocalcaemia – report of six cases and review of the literature
by: Veronika Kreutle, et al.
Published: (2014-06-01)

Thalassaemia: the dental implications of bisphosphonate therapy
by: Navdeep Kumar
Published: (2014-12-01)

Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: a Histological Evaluation
by: Saeed Moradi, et al.
Published: (2023-03-01)

Risk factors for postoperative infectious complications after RIRS treatment of kidney and ureteral stones
by: Tomasz Stachura, et al.
Published: (2022-09-01)